BioSpace News Archive

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System.

CANTEL MEDICAL CORP. will release the results for its second quarter ended January 31, 2019 on Thursday, February 28, 2019 before the market opens, and hold a conference call to discuss the results at 9:30 a.m. ET.

Universal Health Services, Inc. (NYSE: UHS) announced today that Steve Filton, Executive Vice President and Chief Financial Officer will present at the 8th Annual Leerink Partners Healthcare Conference in New York, NY on Friday, March 1, 2019 at 10:30 AM (ET).